Mendus AB (Sweden) Performance
| IMMU Stock | SEK 5.80 0.13 2.19% |
The company secures a Beta (Market Risk) of 0.66, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mendus AB's returns are expected to increase less than the market. However, during the bear market, the loss of holding Mendus AB is expected to be smaller as well. At this point, Mendus AB has a negative expected return of -0.31%. Please make sure to verify Mendus AB's total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to decide if Mendus AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Mendus AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 167.6 M | |
| Total Cashflows From Investing Activities | -1.4 M |
Mendus |
Mendus AB Relative Risk vs. Return Landscape
If you would invest 734.00 in Mendus AB on October 28, 2025 and sell it today you would lose (154.00) from holding Mendus AB or give up 20.98% of portfolio value over 90 days. Mendus AB is generating negative expected returns and assumes 4.2022% volatility on return distribution over the 90 days horizon. Simply put, 37% of stocks are less volatile than Mendus, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Mendus AB Target Price Odds to finish over Current Price
The tendency of Mendus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.80 | 90 days | 5.80 | about 46.48 |
Based on a normal probability distribution, the odds of Mendus AB to move above the current price in 90 days from now is about 46.48 (This Mendus AB probability density function shows the probability of Mendus Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Mendus AB has a beta of 0.66. This usually indicates as returns on the market go up, Mendus AB average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Mendus AB will be expected to be much smaller as well. Additionally Mendus AB has an alpha of 0.0681, implying that it can generate a 0.0681 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Mendus AB Price Density |
| Price |
Predictive Modules for Mendus AB
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mendus AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Mendus AB Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Mendus AB is not an exception. The market had few large corrections towards the Mendus AB's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mendus AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mendus AB within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | 0.66 | |
σ | Overall volatility | 0.68 | |
Ir | Information ratio | 0.01 |
Mendus AB Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mendus AB for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mendus AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Mendus AB generated a negative expected return over the last 90 days | |
| Mendus AB has high historical volatility and very poor performance | |
| Net Loss for the year was (130.1 M) with profit before overhead, payroll, taxes, and interest of 6 K. | |
| Mendus AB has accumulated about 155.31 M in cash with (138.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.94. | |
| Roughly 58.0% of the company shares are held by company insiders |
Mendus AB Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Mendus Stock often depends not only on the future outlook of the current and potential Mendus AB's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Mendus AB's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 184 M | |
| Cash And Short Term Investments | 155.3 M |
Mendus AB Fundamentals Growth
Mendus Stock prices reflect investors' perceptions of the future prospects and financial health of Mendus AB, and Mendus AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mendus Stock performance.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (69.15) % | |||
| Current Valuation | 607.17 M | |||
| Shares Outstanding | 199.4 M | |||
| Price To Earning | (4.53) X | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 354.29 X | |||
| EBITDA | (128.28 M) | |||
| Cash And Equivalents | 155.31 M | |||
| Cash Per Share | 3.94 X | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | 2.81 X | |||
| Cash Flow From Operations | (138.03 M) | |||
| Earnings Per Share | (0.63) X | |||
| Total Asset | 720.98 M | |||
| Retained Earnings | (100 M) | |||
| Current Asset | 45 M | |||
| Current Liabilities | 9 M | |||
About Mendus AB Performance
Assessing Mendus AB's fundamental ratios provides investors with valuable insights into Mendus AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Mendus AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.Things to note about Mendus AB performance evaluation
Checking the ongoing alerts about Mendus AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mendus AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mendus AB generated a negative expected return over the last 90 days | |
| Mendus AB has high historical volatility and very poor performance | |
| Net Loss for the year was (130.1 M) with profit before overhead, payroll, taxes, and interest of 6 K. | |
| Mendus AB has accumulated about 155.31 M in cash with (138.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.94. | |
| Roughly 58.0% of the company shares are held by company insiders |
- Analyzing Mendus AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mendus AB's stock is overvalued or undervalued compared to its peers.
- Examining Mendus AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mendus AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mendus AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mendus AB's stock. These opinions can provide insight into Mendus AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.